Will 2026 Mark The End Of The "Silent Killer" With New NASH Breakthroughs
For decades, non-alcoholic steatohepatitis (NASH) has been a growing global crisis with no approved medical cure, but 2026 has completely changed the landscape. We are seeing a massive shift as the first wave of targeted therapies, including thyroid hormone receptor-beta agonists and FXR ligands, move into widespread clinical use.
1 View